INGELHEIM, Germany and INDIANAPOLIS, US - Tuesday, September 24th 2013 [ME NewsWire]
Pooled analysis of trial data showed linagliptin was well tolerated including in the elderly with normal renal function to severe renal impairment
The overall incidence of adverse events was similar for linagliptin compared to placebo
(BUSINESS WIRE)-- For Non-US and Non-UK Media
Poster No. 926 & 986
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented at the 49th European Association of Diabetes (EASD) Annual Meeting.
General safety analysis
Findings from a pooled comprehensive analysis of safety data in 22 linagliptin clinical trials with 7,400 people with T2D (4,810 received linagliptin, 2,590 received placebo) included the following:1
Linagliptin was well tolerated overall and across all age groups studied, with a low incidence of hypoglycemic events
In an exploratory analysis, overall hypoglycaemia was lower for linagliptin compared to placebo (11.5 percent versus 14 percent, p=0.0021)
Overall incidence of adverse events (AE) or serious adverse events (SAE) with linagliptin was similar to placebo (AE 56.5 percent versus 61.2 percent, and SAE 4.8 percent versus 6.3 percent, respectively)
The incidence of AEs with linagliptin compared to placebo remained similar irrespective of the age category (≤65 years, 65-74 years, ≥75 years)
“Drug tolerability is an important consideration in the selection of appropriate treatments for people with Type 2 Diabetes, as often different populations will have drug contra-indications and require dose adjustments to manage their disease,” said Prof. Nikolaus Marx, Professor of Medicine and Cardiology, University Hospital of Aachen, Germany. “The results presented today support the safety profile of linagliptin.”
Renal safety in the elderly
Results from a post-hoc analysis of pooled data from seven clinical trials including 1,293 people with T2D aged 65 years or older showed:2
Linagliptin was well tolerated providing clinical efficacy in an elderly population with renal function ranging from normal to severe renal impairment
Overall renal function was not significantly altered by treatment with linagliptin from baseline to week 24, versus placebo
Patients taking linagliptin achieved a HbA1c reduction of -0.6 percent from baseline and −0.8 mmol/L for fasting plasma glucose (both values placebo-corrected)
The overall incidence of AEs with linagliptin was similar to placebo (71.3 percent versus 72.8 percent, respectively)
Incidence of investigator-defined hypoglycaemia was not higher in patients who received linagliptin compared to those receiving placebo (21.3 percent versus 24.7 percent), with most events occurring in the trials that included a sulphonylurea or basal insulin as background therapy
Renal and urinary AEs were experienced by 5.5 percent and 4.3 percent of linagliptin and placebo patients, respectively
“The data presented from these analyses supplement the already established evidence demonstrating that linagliptin is a well-tolerated treatment for a broad range of people with Type 2 Diabetes,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “This should provide physicians further assurance when treating different patient types with linagliptin.”
The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and several other regulatory authorities worldwide have approved linagliptin for the treatment of adults with T2D as monotherapy or in combination with metformin, metformin + sulphonylurea, and as add-on therapy to insulin. With linagliptin, no dose adjustment is required regardless of renal function or hepatic impairment.3,4
About Linagliptin
Linagliptin (5 mg) is marketed in Europe as Trajenta® (linagliptin) and in the U.S. as Tradjenta® (linagliptin), as a once-daily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).3,4
Please click on the link below for ‘Notes to Editors’ and ‘References’
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/24_september_2013linagliptin.html
Contacts
Boehringer Ingelheim GmbH
Dr. Petra Kienle
Launch and Established Products CVM
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77-143877
Lilly Diabetes
Tammy Hull
Communications Manager
Email: hullta@lilly.com
Phone: +1 (317) 651 9116
Permalink: http://www.me-newswire.net/news/8602/en
Pooled analysis of trial data showed linagliptin was well tolerated including in the elderly with normal renal function to severe renal impairment
The overall incidence of adverse events was similar for linagliptin compared to placebo
(BUSINESS WIRE)-- For Non-US and Non-UK Media
Poster No. 926 & 986
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented at the 49th European Association of Diabetes (EASD) Annual Meeting.
General safety analysis
Findings from a pooled comprehensive analysis of safety data in 22 linagliptin clinical trials with 7,400 people with T2D (4,810 received linagliptin, 2,590 received placebo) included the following:1
Linagliptin was well tolerated overall and across all age groups studied, with a low incidence of hypoglycemic events
In an exploratory analysis, overall hypoglycaemia was lower for linagliptin compared to placebo (11.5 percent versus 14 percent, p=0.0021)
Overall incidence of adverse events (AE) or serious adverse events (SAE) with linagliptin was similar to placebo (AE 56.5 percent versus 61.2 percent, and SAE 4.8 percent versus 6.3 percent, respectively)
The incidence of AEs with linagliptin compared to placebo remained similar irrespective of the age category (≤65 years, 65-74 years, ≥75 years)
“Drug tolerability is an important consideration in the selection of appropriate treatments for people with Type 2 Diabetes, as often different populations will have drug contra-indications and require dose adjustments to manage their disease,” said Prof. Nikolaus Marx, Professor of Medicine and Cardiology, University Hospital of Aachen, Germany. “The results presented today support the safety profile of linagliptin.”
Renal safety in the elderly
Results from a post-hoc analysis of pooled data from seven clinical trials including 1,293 people with T2D aged 65 years or older showed:2
Linagliptin was well tolerated providing clinical efficacy in an elderly population with renal function ranging from normal to severe renal impairment
Overall renal function was not significantly altered by treatment with linagliptin from baseline to week 24, versus placebo
Patients taking linagliptin achieved a HbA1c reduction of -0.6 percent from baseline and −0.8 mmol/L for fasting plasma glucose (both values placebo-corrected)
The overall incidence of AEs with linagliptin was similar to placebo (71.3 percent versus 72.8 percent, respectively)
Incidence of investigator-defined hypoglycaemia was not higher in patients who received linagliptin compared to those receiving placebo (21.3 percent versus 24.7 percent), with most events occurring in the trials that included a sulphonylurea or basal insulin as background therapy
Renal and urinary AEs were experienced by 5.5 percent and 4.3 percent of linagliptin and placebo patients, respectively
“The data presented from these analyses supplement the already established evidence demonstrating that linagliptin is a well-tolerated treatment for a broad range of people with Type 2 Diabetes,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “This should provide physicians further assurance when treating different patient types with linagliptin.”
The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and several other regulatory authorities worldwide have approved linagliptin for the treatment of adults with T2D as monotherapy or in combination with metformin, metformin + sulphonylurea, and as add-on therapy to insulin. With linagliptin, no dose adjustment is required regardless of renal function or hepatic impairment.3,4
About Linagliptin
Linagliptin (5 mg) is marketed in Europe as Trajenta® (linagliptin) and in the U.S. as Tradjenta® (linagliptin), as a once-daily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).3,4
Please click on the link below for ‘Notes to Editors’ and ‘References’
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/24_september_2013linagliptin.html
Contacts
Boehringer Ingelheim GmbH
Dr. Petra Kienle
Launch and Established Products CVM
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77-143877
Lilly Diabetes
Tammy Hull
Communications Manager
Email: hullta@lilly.com
Phone: +1 (317) 651 9116
Permalink: http://www.me-newswire.net/news/8602/en